Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia

European Journal of Clinical Pharmacology

Volumn 68, Issue 12, 2012, Pages 1577-1586

  Varatharajan, Savitha ^a   Abraham, Ajay ^a   Zhang, Wei ^b   Shaji, R V ^a   Ahmed, Rayaz ^a   Abraham, Aby ^a   George, Biju ^a   Srivastava, Alok ^a   Chandy, Mammen ^a   Mathews, Vikram ^a   Balasubramanian, Poonkuzhali ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Acute myeloid leukemia; Carbonyl reductase; CBR1; CBR3; Daunorubicin; Polymorphism

Indexed keywords

CARBONYL REDUCTASE; CARBONYL REDUCTASE 1; CARBONYL REDUCTASE 3; DAUNORUBICIN; DAUNORUBICINOL; MESSENGER RNA; RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER RESISTANCE; CELL LEVEL; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; FEMALE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PHARMACOGENETICS; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; ALCOHOL OXIDOREDUCTASES; ANTIBIOTICS, ANTINEOPLASTIC; CELLS, CULTURED; DAUNORUBICIN; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER; YOUNG ADULT;

EID: 84871312029     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1291-9     Document Type: Article

References (41)

1. Weiss RB (1992) The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19(6):670-686
2. Rabbani A, Finn RM, Ausio J (2005) The anthracycline antibiotics: antitumor drugs that alter chromatin structure. Bioessays 27 (1):50-56
3. Frohling S, Scholl C, Gilliland DG, Levine RL (2005) Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 23(26):6285-6295
4. Schiffer CA, McIntyre OR (1993) Age related changes in adults with acute leukemia. Adv Exp Med Biol 330:215-229
5. Burnett AK, Mohite U (2006) Treatment of older patients with acute myeloid leukemia-new agents. Semin Hematol 43(2):96- 106
6. Kuffel MJ, Reid JM, Ames MM (1992) Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol 30(1):51-57
7. Oppermann U (2007) Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology. Annu Rev Pharmacol Toxicol 47:293-322
8. Plebuch M, Soldan M, Hungerer C, Koch L, Maser E (2007) Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes. Cancer Lett 255(1):49-56
9. Takahashi RH, Bains OS, Pfeifer TA, Grigliatti TA, Reid RE, Riggs KW (2008) Aldo-keto reductase 1C2 fails to metabolize doxorubicin and daunorubicin in vitro. Drug Metab Dispos 36 (6):991-994
10. Kassner N, Huse K, Martin HJ, Godtel-Armbrust U, Metzger A, Meineke I et al (2008) Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos 36 (10):2113-2120
11. Forrest GL, Gonzalez B (2000) Carbonyl reductase. Chem Biol Interact 129(1-2):21-40
12. Watanabe K, Sugawara C, Ono A, Fukuzumi Y, Itakura S, Yamazaki Met al (1998)Mapping of a novel human carbonyl reductase, CBR3, and ribosomal pseudogenes to human chromosome 21q22.2. Genomics 52(1):95-100
13. Liu S, Ma L, Huang W, Shai Y, Ji X, Ding L et al (2006) Decreased expression of the human carbonyl reductase 2 gene HCR2 in hepatocellular carcinoma. Cell Mol Biol Lett 11(2):230-241
14. Gonzalez B, Akman S, Doroshow J, Rivera H, Kaplan WD, Forrest GL (1995) Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. Cancer Res 55(20):4646-4650
15. Huang W, Ding L, Huang Q, Hu H, Liu S, Yang X et al (2010) Carbonyl reductase 1 as a novel target of (-)-epigallocatechin gallate against hepatocellular carcinoma. Hepatology 52(2):703-714
16. Bogason A, Masquelier M, Lafolie P, Skogastierna C, Paul C, Gruber A et al (2010) Daunorubicin metabolism in leukemic cells isolated from patients with acute myeloid leukemia. Drug Metab Lett 4(4):228-232
17. Gonzalez-Covarrubias V, Ghosh D, Lakhman SS, Pendyala L, Blanco JG (2007) A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity. Drug Metab Dispos 35(6):973-980
18. Bains OS, Karkling MJ, Grigliatti TA, Reid RE, Riggs KW (2009) Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin. Drug Metab Dispos 37(5):1107- 1114
19. Lakhman SS, Ghosh D, Blanco JG (2005) Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3). Drug Metab Dispos 33(2):254-257
20. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM, Relling MV et al (2008) Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112(12):2789-2795
21. Fan L, Goh BC, Wong CI, Sukri N, Lim SE, Tan SH et al (2008) Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet Genomics 18(7):621-631
22. Lal S, Sandanaraj E, Wong ZW, Ang PC, Wong NS, Lee EJ et al (2008) CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 99(10):2045-2054
23. Kokenberg E, Sonneveld P, Sizoo W, Hagenbeek A, Lowenberg B (1988) Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia. J Clin Oncol 6(5):802-812
24. Poonkuzhali B, Srivastava A, Quernin MH, Dennison D, Aigrain EJ, Kanagasabapathy AS et al (1999) Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 24(1):5-11
25. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M et al (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55(4):611-622
26. Borg AG, Burgess R, Green LM, Scheper RJ, Liu Yin JA (2000) P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells. Br J Haematol 108 (1):48-54
27. Fogli S, Danesi R, Innocenti F, Di Paolo A, Bocci G, Barbara C et al (1999) An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. Ther Drug Monit 21(3):367-375
28. Pieters R, Loonen AH, Huismans DR, Broekema GJ, Dirven MW, Heyenbrok MWet al (1990) In vitro drug sensitivity of cells from children with leukemia using the MTTassay with improved culture conditions. Blood 76(11):2327-2336
29. Klumper E, Pieters R, Kaspers GJ, Huismans DR, Loonen AH, Rottier MM et al (1995) In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia. Leukemia 9(11):1864-1869
30. D'Argenio DZ, Schumitzky A, Wang X (2009) ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles
31. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2):263-265
32. Lewontin RC (1964) The interaction of selection and linkage. I. General considerations; heterotic models. Genetics 49(1):49-67
33. Hochberg Y, Ba Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B: Methodol 57(1):11
34. Speth PA, Linssen PC, Boezeman JB, Wessels HM, Haanen C (1987) Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion. Cancer Chemother Pharmacol 20(4):311-315
35. Terada T, Sugihara Y, Nakamura K, Mizobuchi H, Maeda M (2003) Further characterization of Chinese hamster carbonyl reductases (CHCRs). Chem Biol Interact 143-144:373-381
36. Zhang Y, Rohde C, Tierling S, Jurkowski TP, Bock C, Santacruz D et al (2009) DNA methylation analysis of chromosome 21 gene promoters at single base pair and single allele resolution. PLoS Genet 5(3):e1000438
37. Gonzalez-Covarrubias V, Zhang J, Kalabus JL, Relling MV, Blanco JG (2009) Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors. Drug Metab Dispos 37(2):400-407
38. Bains OS, Karkling MJ, Lubieniecka JM, Grigliatti TA, Reid RE, Riggs KW (2010) Naturally occurring variants of human CBR3
39. alter anthracycline in vitro metabolism. J Pharmacol Exp Ther 332 (3):755-763
40. Galettis P, Boutagy J, Ma DD (1994) Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia. Br J Cancer 70(2):324-329
41. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM (2007) Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res 67(20):9609- 9612